Drug Profile


Alternative Names: VEGF antisense oligonucleotide - VasGene Therapeutics; VEGF-AS

Latest Information Update: 22 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idera Pharmaceuticals; University of Southern California; VasGene Therapeutics
  • Developer VasGene Therapeutics
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Kaposi's sarcoma; Mesothelioma; Renal cancer

Most Recent Events

  • 22 Jan 2016 Discontinued - Phase-I for Cancer in USA (IV)
  • 22 Jan 2016 Discontinued - Phase-I for Kaposi's sarcoma in USA (unspecified route)
  • 22 Jan 2016 Discontinued - Phase-I for Mesothelioma (Combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top